Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells.

Alessia PotenzaChiara BalestrieriMartina SpigaLuca AlbarelloFederica PedicaFrancesco ManfrediBeatrice Claudia CianciottiClaudia De LallaOronza A BotrugnoCristina FaccaniLorena StasiElena TassiSilvia BonfiglioGiulia Maria ScottiMiriam RedegalliDonatella BiancoliniBarbara CamisaElena TizianoCamilla SiriniMonica CasucciChiara IozziDanilo AbbatiFabio SimeoniDejan LazarevicUgo ElmoreGuido FiorentiniGiulia Di LulloGiulia CasoratiClaudio DoglioniGiovanni TononPaolo DellabonaRiccardo RosatiLuca AldrighettiEliana RuggieroChiara Bonini

Published in: Gut (2023)

HER-2-specific CD39 disrupted engineered T cells are promising advanced medicinal products for primary and metastatic CRC.

Keyphrases

liver metastases
squamous cell carcinoma
small cell lung cancer
nk cells
machine learning
resting state
replacement therapy
functional connectivity